Strategy and tactics of treatment of type 2 diabetes mellitus


Authors: Milan Kvapil
Published in: Vnitř Lék 2019; 65(4): 273-278
Category:

Overview

The results of randomized double-blind studies provide scientifically accurate data on the efficacy of antidiabetic drugs. With the widening understanding of heterogeneity of the group of patients with type 2 diabetes mellitus and the broadening possibilities of interventions available, a differentiated approach to therapy is now accentuated. From the perspective of pathophysiology, 8–10 different disorders have been described which contribute to the occurrence of hyperglycemia, but they cannot be quantified in common practice. However, it is possible to evaluate the amount of insulin secretion (C-peptide), the presence or severity of insulin resistance (triacylglycerols), glomerular filtration and, of course, patient compliance. The strategic goal of treatment of diabetes mellitus is to reduce the risk of late complications, both specific and non-specific (atherosclerotic), and if they arise, then slowing-down of their progression. All of this as a means of reducing mortality and improving quality of life. The tactics of therapy for type 2 diabetes mellitus must first of all be chosen individually. We bear in mind the general circumstances (life expectancy, comorbidities, age, compliance, social background, type of work) and specific characteristics of the current development of diabetes (the dominant nature of metabolic disorder, the level of preservation of insulin secretion or response to prandial stimulation, presence and progression of complications). A timely combination of 2 or more antidiabetic drugs targeting individual pathophysiological mechanisms can be considered useful.

Keywords:

antidiabetics – compliance – therapy failure – type 2 diabetes mellitus


Sources
  1. Tsujimoto T, Kajio H, Sugiyama T Favourable changes in mortality in p1. Tsujimoto T, Kajio H, Sugiyama T. Favourable changes in mortality in people with diabetes: US NHANES 1999–2010. Diabetes Obes Metab 2018; 20(1): 85–93. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13039>.

  2. Brož J, Honěk P, Dušek L et al. Mortalita pacientů s diabetes mellitus léčených perorálními antidiabetiky v České republice poklesla během let 2003–2013 a přiblížila se populačnímu průměru. (Souběžný název: The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003–2013 and came closer to the population average). Vnitř Lék 2015; 61(11 Suppl 3): 3S14–3S20.

  3. ZDRAVOTNICTVÍ ČR. Stručný přehled mortalitních dat ČR z listu o prohlídce zemřelého 2004–2015. NZIS REPORT č. R/2 (09/2016. Dostupné z WWW: <https://www.uzis.cz/system/files/NZIS_REPORT_c_R02_09_16_LPZ.pdf>.

  4. Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes (Basel) 2015; 6(1): 87–123. Dostupné z DOI: <http://dx.doi.org/10.3390/genes6010087>.

  5. Dangi-Garimella S. The role of bioinformatics in diabetes drug development and precision medicine. Am J Manag Care 2014; 20 (8 Spec No): E1.

  6. Filipova E, Uzunova K, Kalinov K et al. Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis. Diabetol Metab Syndr 2017; 9: 90. Dostupné z DOI: <http://dx.doi.org/10.1186/s13098–017–0290–5>.

  7. Kernan WN, Viscoli CM, Furie KL et al. [IRIS Trial Investigators]. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med 2016; 374(14): 1321–1331. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1506930>.

  8. Gotthardová I, Javorský M, Klimčáková L et al. KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors. Diabetes Res Clin Pract 2017; 130: 142–147. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2017.05.018>.

  9. Saunders C, Byrne CD, Guthrie B et al. [Scottish Diabetes Research Network Epidemiology Group]. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med 2013; 30(3): 300–308. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.12047>.

  10. Tsapas A, Matthews DR. N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia 2008; 51(6): 921–925. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–008–0983–2>.

  11. Cook EF, Goldman L. Performance of tests of significance based on stratification by a multivariate confounder score or by a propensity score. J Clin Epidemiol 1989; 42(4): 317–324.

  12. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. Guidance for Industry and Food and Drug Administration Staff. Document issued on August 31, 2017. Dostupné z WWW: <https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm513027.pdf>.

  13. Cersosimo E, Triplitt C, Solis-Herrera C et al. Pathogenesis of Type 2 Diabetes Mellitus. Dostupné z WWW: <https://www.ncbi.nlm.nih.gov/pubmed/25905339>.

  14. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974; 57(4): 551–560.

  15. Kvapil M. Kombinační léčba perorálními antidiabetiky. Kardiol Rev Int Med 2014; 16(6): 454–457.

  16. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006; 22(6): 423–436. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.634>.

  17. Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

  18. Inzucchi SE, Zinman B, Fitchett D et al. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2018; 41(2): 356–363. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17–1096>.

  19. Wilcox R, Kupfer S, Erdmann E. [PROactive Study investigators]. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008; 155(4): 712–717. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2007.11.029>. Erratum in Am Heart J 2008; 156(2): 255.

  20. Marso SP, Daniels GH, Brown-Frandsen K et al. [LEADER Steering Committee; LEADER Trial Investigators]. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.

  21. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415–427. Dostupné z DOI: <http://dx.doi.org/10.2147/VHRM.S33664>.

  22. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab 2005; 90(10): 5896–5903. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2005–0754>.

  23. Piťhová P, Honěk P, Dušek L et al. Incidence amputací u pacientů s diabetes mellitus v České republice v letech 2010–2014. Vnitř Lék 2015; 61(11 Suppl 3): 3S21–3S24.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 4

2019 Issue 4

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account